Korea Research Institute of Chemical Technology

141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea

Phone: +82-42-860-7176, +1-617-674-4398

E-Mail Address: kwangho@krict.re.kr

ACCOMPLISHMENT

·         Discovery of KTA-33 & KTA-43 for ASK1 inhibition: licensed out (2023), preclinical study

·         Discovery of YH42946 (JIN-A04) for HER2 mutants inhibition: licensed out to 제이인츠바이오 (2021), sublicensed to Yuhan (2023): Ph1 study on-going.

·         Discovery of JIN-A02 for EGFR C797S mutants inhibition: licensed out to 제이인츠바이오 (2021): Ph2 study on-going.

·         Discovery of TREA-313 for EGFR L858R allosteric inhibition: licensed out to HK이노엔 (2019): preclinical study

·         Discovery of BBT-176 for EGFR T790M/C797S inhibition: licensed out to Bridge Biotherapeutics Inc. (2018), terminated after Phase1 

·         Discovery of DRAK2 inhibitor TRD-0257: licensed out to 메드팩토 (2017)

·         Discovery of BBT-401 for Pellino-1 inhibition: licensed out to Bridge Biotherapeutics Inc. (2015), Ph2 study on-going.

·         Discovery of BD1-selective BET inhibitor: licensed out to 동화약품(2015)

·         Discovery of selective Ack1 inhibitor: licensed out to ㈜인투셀 (2015)

·         Discovery of ABN401 for selective c-MET inhibition: licensed out to 에이비온 (2014), Ph2 study on-going.

·         Discovery of Rociletinib (CO-1686) for Epithermal Growth Factor Receptor (EGFR) mutant selective inhibitors (EMSI): licensed to Clovis Oncology for $209M, terminated after Phase3

·         Discovery of LFF571 a novel Elongation Factor Tu (EFTU) inhibitor: terminated after Phase2

·         Discovery of LBM415 Peptide Deformylase Inhibitors (PDF): terminated after Phase1

EXPERIENCE/RESPONSIBILITY

2011- Current       Korea Research Institute of Chemical Technology

Principal Investigator  Drug & Bio Research Division

2012- Current       Korea National University of Science & Technology

                            Professor (Medicinal Chemistry & Pharmacology)

2012- 2018           Translational Research Institute of Novel Drug (TREND)

Principal Investigator (과기정통부 기초연계중개연구 과제책임자)

2008- 2011           Avila Therapeutics (merged into Bristol Myers Squibb)

Program Team Head (Principal Scientist) Platform study and Oncology area research.  covalent inhibition on specific ligand binding.  Inhibitors of Apoptosis (IAP), Epithermal Growth Factor Receptor (EGFR) Mutant Selective Inhibitors (EMSI), Bruton’s Tyrosine Kinase (BTK) inhibitors for RA and Oncology.

2003- 2008           Novartis Institutes for BioMedical Research, Inc.

Research Investigator I - II  Infectious Disease area research (Peptide Deformylase Inhibitors (PDF), Undecaprenyl Pyrophosphate Synthase Inhibitors (UPPS), HCV NS3/4A protease inhibitors, Elongation Factor Tu inhibitors (EFTU) and Bacteria Growth Inhibition (BGI): Phenotypic Antibacterial Screening).

1992-1997               CJ Co., Kyunggi-do, Korea

Senior Research Associate Five and a half years pharmaceutical experience in new drug study on antibacterial drugs (2-Oxazolidinones, Quinolones, and Cephalosporines).

EDUCATION

Harvard University, Postdoctoral Fellow, June 2001 - March 2003 (Advisor: Professor Yoshito Kishi)

The University of Alabama, Ph D. Organic Chemistry, August 1997 - May 2001 (Advisor: Professor Jin K. Cha)

Seoul National University, M.S. Organic Chemistry, March 1990 - February 1992 (Advisor: Professor Eun Lee)

Seoul National University, B.S. Chemistry, March 1986 - February 1990

PUBLICATIONS

“Discovery of BBT-176 as a Fourth-Generation EGFR Tyrosine Kinase Inhibitor” Duggirala, K. B.; Choe, H.; Jeon, B. U.; Park, C.; Yoon, J.; Kim, H.; Jung, M. E.; Choi, G.; Chae, C. H.; Cho, B. C.; Lee, K. Results in Chemistry 2025, 16, 102406.

“Discovery of 2-(1,2,4-triazol-3-yl)pyridine KTD-092 as a novel DYRK1A inhibitor” Hong, S.; Hwang, S.; Cyriac, R.; Choi, H.; Choi, G.; Kim, E. H.; Lee, C.; Kim, S. H.; Ahn, S.; Chae, C. H.; Song, J. S.; Lee, K. Bull. Korean Chem. Soc. 2025, 46, 520.

“Discovery of benzimidazole-2-amide BNZ-111 as new tubulin inhibitor” Jang, J.; Koh, B.; Lee, K. Bioorg. Med. Chem. Lett. 2024, 113, 129953. 

“Novel Allosteric Glutaminase Inhibitors with Macrocyclic Structure Activity Relationship Analysis (Part 2)” Lee, E. J.; Jang, J.; Cyriac, R.; Yun, M. R.; Kwon, Y.; Jung, M. E.; Choi, G.; Chae, C. H.; Cho, B. C.; Lee, K. Bull. Korean Chem. Soc. 2024, 45, 639.

“Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer” Koh, B.; Ryu, J.-Y.; Noh, J. J.; Hwang, J. R.; Choi, J.-J.; Cho, Y.-J.; Jang, J.; Jo, J. H.; Lee, K.; Lee, J.-W. Gynecol. Oncol. 2024, 188, 60.

“DW71177: A Novel [1,2,4]triazolo[4,3-a]quinoxaline-Based Potent and BD1-Selective BET Inhibitor for the Treatment of Acute Myeloid Leukemia” Ali, I.; Cha, H. J.; Lim, B.; Chae, C. H.; Youm, J.; Park, W. J.; Lee, S. H.; Kim, J. H.; Jeong, D.; Lim, J. K.; Hwang, Y.-H.; Roe, J.-S.; Woo, J.-S.; Lee, K.; Choi, G. Eur. J. Med. Chem. 2024, 265, 116052.

“Glutaminase inhibition as potential cancer therapeutics: current status and future applications” Cyriac, R.; Lee, K. J. Enzyme Inhib. Med. Chem. 2024, 39(1), 2290911.

“Discovery of TRD-93 as a novel DRAK2 inhibitor” Park, S.; Kye, S.; Jung, M. E.; Chae, C. H.; Yang, K.-M.; Kim, S.-J.; Choi, G.; Lee, K. Bull. Korean Chem. Soc. 2023, 44, 395.

“Novel Allosteric Glutaminase 1 Inhibitors with Macrocyclic Structure Activity Relationship Analysis” Lee, E. J.; Duggirala, K. B.; Lee, Y.; Yun, M. R.; Jang, J.; Cyriac, R.; Jung, M. E.; Choi, G.; Chae, C. H.; Cho, B. C.; Lee, K. Bioorg. Med. Chem. Lett. 2022, 75, 128956.

“Investigation of benzimidazole anthelmintics as oral anticancer agents” Jang, J.; Lee, K.; Koh, B. Bull. Korean Chem. Soc. 2022, 43, 750.

“Chronicles of EGFR tyrosine kinase inhibitors: Targeting EGFR C797S containing triple mutations” Duggirala, K. B.; Lee, Y.; Lee, K. Biomol. Ther. 2022, 30(1), 19.

“Rotational Variance-Based Data Augmentation in 3D Graph Convolutional Networks” Kim, J.; Kim, Y.; Lee, E. K.; Chae, C. H.; Lee, K.; Kim, W. J.; Choi, I. S. Chem. Asian J. 2021, 16, 2610.

“Identification of new IL-7Rα small-molecule agonists: a multi-computational approach” Lee, J.-Y.; Lee, K.; Koh, B. SAR QSAR Environ. Res. 2021, 32(9), 719.

“Rational design, synthesis and evaluation of novel C6-bicycloalkaneimidazole containing imidazo[1,2-b]pyridazines for ASK1 inhibition” Lee, Y.; Jang, J.; Bibi, M.; Duggirala, K. B.; Jim S. H.; Lee, J. H.; Ahn, S.; Song, J. S.; Chae, C. H.; Kim, S. H.; Lee, K. Bull. Korean Chem. Soc. 2021, 42, 872.

“KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth” Hwang, J.; Song, I.; Lee, K.; Kim, H. R.; Hong, E.-H.; Hwang, J. S.; Ahn, S.-H.; Lee, J. Invest. New Drugs 2020, 38, 1282.

“Identification of TRD-35 as potent and selective DRAK2 inhibitor” Ali, I.; Park, S.; Jung, M. E.; Lee, N.; Bibi, M.; Chae, C. H.; Yang, K.-M.; Kim, S.-J.; Choi, G.; Lee, K. Bull. Korean Chem. Soc. 2020, 41, 567. [selected as cover article]

 “Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene” Kim, B.; Jo, S.; Park, S. B.; Chae, C. K.; Lee, K.; Koh, B.; Shin, I. Bioorg. Med. Chem. Lett. 2020, 30, 126756.

“The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer” S. Y. Jun; S.-J. Jeon; J.-Y. Yoon; J.-J. Lee; H. R. Yoon; M.-H. Choi; D. Halder; K. Lee; N.-S. Kim Scientific Reports 2019, 9, 16802.

“Identification of TRE-130 as reversible inhibitor of pan-EGFR mutants while sparing EGFR wild-type activity” Duggirala, K. B.; Choe, H.; Jeon, B. U.; Jung, M. E.; Go, A.; Lim, B.; Park, C.; Yoon, J.; Chae, C. H.; Cho, B. C.; Choi, G.; Lee, K. Bull. Korean Chem. Soc. 2019, 40, 1222.

 “Novel Indazole-Based MKK7-TIPRL Interaction Inhibitors as TRAIL Sensitizers” Gu, S.; Jung, M. E.; Yoon, J.-Y.; Yoon, S.-E.; Lee, J.-J.; Lee, K.; Choi, G.; Kim, N.-S.; Jeon, M.-K. Bull. Korean Chem. Soc. 2018, 39, 1125.

“Allosteric inhibitor TREA-0236 containing non-hydrolysable quinazoline-4-one for EGFR T790M/C797S mutants inhibition” Lee, S.; Kim, J.; Duggirala, K. B.; Go, A.; Shin, I.; Cho, B. C.; Choi, G.; Chae, C. H.; Lee, K. Bull. Korean Chem. Soc. 2018, 39, 895.

“Can We Prevent Resistance to Osimertinib? Combination or Sequential” Kim, M. H.; Lim, S. M.; Lee, K.; Soo, R. A.; Cho, B. C. J. Thorac. Onc. 2018, 13, 877.

 “Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma” Y, J.-Y.; Lee, J.-J.; Gu, S.; Jung, M. E.; Cho, H.-S.; Lim, J. H.; Jun, S. Y.; Ahn, J.-H.; Min, J.-S.; Choi, M.-H.; Jeon, S.-J.; Lee, Y.-J.; Go, A.; Heo, Y.-J.; Jung, C.-R.; Choi, G.; Lee, K.; Jeon, M.-K.; Kim, N.-S. Oncotarget 2017, 8, 112610.

“Bet inhibitors as anticancer agent: a patent review” Ali, I.; Choi, G.; Lee, K. Rec. Patents on Anti-Cancer Drug Dis. 2017, 12, 340.

“Structure–Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment” Choe, H.; Jeon, B. U.; Jung, M. E.; Jeon, M.-K.; Shin, I.; Cho, B. C.; Choi, G.; Chae, C. H.; Lee, K. Bull. Korean Chem. Soc. 2017, 38, 1353. [selected as cover article]

“Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment” Ali, I.; Lee, J.; Go, A.; Choi, G.; Lee, K. Bioorg. Med. Chem. Lett. 2017, 27, 4606.

 “Identification of Pyrrole[3,4-c]pyrazoles as Potent Tropomyosin Receptor Kinase A (TrkA) Inhibitors” Choe, H.; Son, Y. H.; Byun, B. J.; Choi, S. U.; Lee, K. Bull. Korean Chem. Soc. 2016, 37, 1378.

“Antibacterial and Solubility Optimization of Thiomuracin A” LaMarche, M. J.; Leeds, J. A.; Brewer, J.; Dean, K.; Ding, J.; Dzink-Fox, J.; Gamber, G.; Jain, A.; Kerrigan, R.; Krastel, P.; Lee, K.; Lombardo, F.; McKenney, D.; Neckermann, G.; Osborne, C.; Palestrant, D.; Patane, M. A.; Rann, E. M.; Robinson, Z.; Schmitt, E.; Stams, T.; Tiamfook, S.; Yu, D.; Whitehead, L. J. Med. Chem. 2016, 59, 6920.

“신약발굴 중개연구기관 (TREND) 소개” 이광호; 최길돈 화학세계 2016 년 4 월호.

“Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening” Jung, M. E.; Byun, B. J.; Kim, H.-M.; Lee, J. Y.; Park, J.-H.; Lee, N.; Son, Y. H.; Choi, S. U.; Yang, K.-M.; Kim, S.-J.; Lee, K.; Kim, Y.-C.; Choi, G. Bioorg. Med. Chem. Lett. 2016, 26, 2719.

 “Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins” Kang, C. H.; Yun, J. I.; Lee, K.; Lee, C. O.; Lee, H. K.; Yun, C.-S.; Hwang, J. Y.; Cho, S. Y.; Jung, J.; Kim, P.; Ha, J. D.; Jeon, J. H.; Choi, S. U.; Jeong, H. G.; Kim, H. R.; Park, C. H. Biochem. Biophys. Res. Commun. 2015, 464, 762.

“Two minor chalcone acetylglycosides from the roots extract of Glycyrrhiza uralensis” Lee. J. E.; Lee, J. Y.; Kim, J.; Lee, K.; Choi, S. U.; Ryu, S. Y. Arch. Pharm. Res. 2015, 18, 1299.

“NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor” Galvani, E.; Sun, J.; Leon, L. G.; Sciarrillo, R.; Narayan, R. S.; Sjin, R. T. T.; Lee, K.; Ohashi, K.; Heideman, D. A. M.; Alfieri, R. G.; Heynen, G. J.; Bernards, R.; Smit, E. F.; Pao, W.; Peters, G. J.; Giovannetti, E. Oncotarget 2015, 6, 42717.

“Design, synthesis and evaluation of 2-anilino-4-(3,5-dicarboxamidespiperidine)-pyrimidines as anaplastic lymphoma kinase inhibitors” Latif, M.; Park, S.; Ali, I.; Choe, H.; Chae, C. H.; Park, C. H.; Kim, H. R.; Yun, C.-S.; Lee, K. Bull. Korean Chem. Soc. 2015, 36, 2397.

“Synthesis of 4-(3,4-dicarboxamido-1H-pyrrole)pyrimidines as anaplastic lymphoma kinase inhibitors” Latif, M.; Byun, B. J.; Lee, K. Bull. Korean Chem. Soc. 2015, 36, 520.

“Synthesis and biological evaluation of tetrapeptide ketones as reversible 20S proteasome inhibitors” Latif, M.; Jung, M. E.; Lee, K.; Choi, G. Bull. Korean Chem. Soc. 2014, 35, 3571.

“In vitro and In vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors that are Wild-type Sparing” Sjin, R. T. T.; Lee, K.; Walter, A. O.; Dubrovisky, A.; Sheets, M.; St. Martin, T.; Labenski, M.; Zhu, Z.; Tester, R.; Karp, R.; Medikonda, A.; Chaturvedi, P.; Ren, Y.; Haringsma, H.; Etter, J.; Raponi, M.; Simmons, A. D.; Harding, T. C.; Niu, D.; Nacht, M.; Westlin, W.; Petter, R. C.; Allen, A.; Singh, J. Mol. Cancer Ther. 2014, 13(6), 1468.

“ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment” Lee, H. J.; Latif, M.; Choe, H.; Ali, I.; Lee, H. K.; Yang, E. H.; Yun, J. I.; Chae, C. H.; Jung, J. –K.; Kim, H. R.; Lee, C. O.; Park, C. H.; Lee, K. Arch. Pharm. Res. 2014, 37, 1130.

“Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities” Yun, J. I.; Yang, E. H.; Latif, M.; Lee, H. J.; Lee, K; Yun, C. –S.; Park, C. H.; Lee, C. O.; Chae, C. H.; Cho, S. Y.; Jung, H. J.; Kim, P.; Choi, S. U.; Kim, H. R. Arch. Pharm. Res. 2014, 37, 873.

“3D-QSAR Studies on Chemical Features of 3-(benzo[d]oxazol-2-yl)pyridine-2-amines in the External Region of c-Met Active Site” Lee, J. Y.; Lee, K.; Kim, H. R.; Chae, C. H. Bull. Korean Chem. Soc. 2013, 34, 3553.

“Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC” Walter, A. O.; Sjin, R. T. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M. T.; Zhu, Z.; Wang, Z.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; Dyke, T. V.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Cancer Discovery 2013, 3, 1404.

“New pyrimidine Derivatives possessing ALK inhibitory activities” Yang, E. H.; Yun, J. I.; Latif, M.; Lee, H. J.; Yun, C. -S.; Lee, K.; Park, C. H.; Choi, S. U.; Jung, H. J.; Kim, P.; Ha, J. D.; Kim, H. R. Bull. Korean Chem. Soc. 2013, 34, 3129.

“Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment” Park, C. H.; Choe, H.; Jang, I.-Y.; Kwon, S. Y.; Latif, M.; Lee, H. K.; Lee, H. J.; Yang, E. H.; Yun, J. I.; Chae, C. H.; Cho, S. Y.; Choi, S. U.; Ha, J. D.; Jung, H.; Kim, H. R.; Kim, P.; Lee, C. O.; Yun, C. -S.; Lee, K. Bioorg. Med. Chem. Lett. 2013, 23, 6192.

“Synthesis and structure–activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors” Lee, J.; Han, S. –Y.; Jung, H.; Yang, J.; Choi, J. –W.; Chae, C. H.; Park, C. H.; Choi, S. U.; Lee, K.; Ha, J. D.; Lee, C. O.; Ryu, J. W.; Kim, H. R.; Koh, J. S.; Cho, S. Y. Bioorg. Med. Chem. Lett. 2012, 22, 4044.

“Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors” Han, S. –Y.; Choi, J. W.; Yang, J.; Chae, C. H.; Lee, J.; Jung, H.; Lee, K.; Ha, J. D.; Kim, H. R.; Cho, S. Y. Bioorg. Med. Chem. Lett. 2012, 22, 2837.

“Discovery of LFF571: An Investgational Agent for Clostridium difficile Infection” LaMarche, M. J.; Leeds, J. A.; Amaral, A.; Brewer, J. T.; Bushell, S.; Dewhurst, J.; Ding, J.; Dzink-Fox, J.; Gamber, G.; Jain, A.; Lee, K.; Lister, T.; McKenney, D.; Mullin, S.; Osborne, C. S.; Palestrant, D.; Patane, M.; Rann, E.; Shao, J.; Tiamfock, S.; Trzasko, A.; Whitehead, L.; Yifru, A.; Yu, D.; Yan, W.; Zhu, Q.; Deng, G.; Lee, L. V.; Sachdeva, M. J. Med. Chem. 2012, 55, 2376.

“Convenient Annulation of Bicyclo[6.3.0]undecanes” Lee, K.; Cha, J. K. Tetrahedron Lett. 2001, 42, 6019-6021.

 “Formal Synthesis of (+)-Phorbol” Lee, K.; Cha, J. K. J. Am. Chem. Soc. 2001, 123, 5590-5591.

 “Enantioselective Synthesis of Unnatural (S)-(+)-Cocaine” Lee, J. C.; Lee, K.; Cha, J. K. J. Org. Chem. 2000, 65, 4773-4775.

 “A New Approach to Phorbol by [4 + 3] Oxyallyl Cycloaddition and Intramolecular Heck Reaction” Lee, K.; Cha, J. K. Org. Lett. 1999, 1, 523-525.

 “Diastereoselective Synthesis of Trisubstituted Cyclopropyl Stannanes” Lee, K.; Kim, S. -I.; Cha, J. K. J. Org. Chem. 1998, 63, 9135-9138.

 “Synthesis and Antibacterial Activity of a New Series of Quinolones with 7-Substituent of [3.1.1] Bicyclic Amines” Kim, J.; Yoon, Y. H.; Cho, I. H.; Lee, J. M.; Lee, K.; Kim, J. H.; Hong, K. H. Korean J. Med. Chem. 1996, 6, 183-189.

 “Stereoselective Reduction of a-Iodospirolactones, Total Synthesis of (+/-)-Liguloxide” Lee, E.; Lee, D.; Choi, Y. W.; Lee, K. Tetrahedron Lett. 1992, 33, 6673-6676.

 “Intramolecular Dimerization of Carbenoids” Lee, E.; Lee, D.; Lee, K.; Choi, I. S. Bull. Korean Chem. Soc. 1992, 13, 470-471.

 “Selectivity in the Lactone Formation via C-H Insertion Reaction of Diazoacetoacetates” Lee, E.; Kim, E. K.; Jung, K. W.; Lee, K. H.; Kim, Y. S.; Lee, K. Bull. Korean Chem. Soc. 1991, 12, 361-363.

PATENTS

“Triazole compound having novel ring structure, method for preparing same, and use thereof” Lee, K.; Song, J. S.; Kim, S. H.; Ahn, S.; Chae, C. H.; Duggirala, K. B.; Lee, Y.; Ji, S. H.; Jang, J. WO2025014332.

“Benzimidazole derivatives, preparation method thereof, and pharmaceutical composition for prevention or treatment of cancer or infectious diseases containing same as active ingredient” Lee, K.; Koh, B. S.; Jang, J. Y. WO2023239007.

“Preparation of pyrimidine derivatives and pharmaceutical compositions for preventing or treating cancer” Lee. K.; Duggirala, K. B.; Choi, G.; Chae, C. H.; Jung, M. E.; Cho, B. C. WO2023014022.

“Novel macrocyclic compound, preparation method therefor, and pharmaceutical composition for preventing or treating cancer or autoimmune diseases, containing same as active ingredient” Lee, K.; Duggirala, K. B.; Lee, Y.; Choi, G.; Chae, C. H.; Jung, M. E.; Cho, B. C.; Yun, M. R. WO2023022430.

“Novel pyrimidine-2,4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer” Lee, K.; Duggirala, K. B.; Choi, G.; Lee, Y.; Chae, C. H.; Jung, M. E.; Cho, B. C. WO2023287130.

“Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient” Kang, S.; Yoon, D.; Kim, H.; Park, S. Y.; Kim, D.; Park, J.-Y.; Byeon, Y.; Jo, H.-I.; Jung, S. H.; Choi, S.-I.; Lee, S. C.; Lee, K. WO 2022245061.

“Benzamide derivative, preparation method therefor, and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer” Lee, K.; Kim, J.; Cho, B. C.; Choi, G.; Yun, J.; Park, C. W.; Chae, C. H.; Duggirala, K. B.; Chae, C. H.; Lee, S. Y.; Go, A. R. WO 2021101268.

“Pyrimidine derivative, method of preparing same, and pharmaceutical composition for preventing or treating cancer, comprising same as effective component” Lee, K.; Cho, B. C.; Duggirala, K. B.; Choi, G.; Yun, J.; Park, C. W.; Chae, C. H.; Jung, M. E. WO 2021075691.

“Preparation of isoindolinone derivatives for prevention or treatment of cancer and method for reparation thereof” Lee, K.; Choi, G.; Lee, S.; Kim, J.; Cho, B. C.; Park, C.; Yun, J. WO 2020036386.

“N2,​N4-​diphenylpyrimidine-​2,​4-​diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer” Lee, K.; Shin, I.; Choi, G.; Chae, C. H.; Choe, H. J.; Jung, M. E.; Jeon, B. U.; Cho, B. C.; Park, C. W.; Kim, H.; Duggirala, K. B. WO 2018230934.

“Novel [1,​2,​4]​triazolo[4, 3-​a]​quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating bet protein-​related diseases, containing same as active ingredient” Lee, K.; Choi, G.; Ali, I.; Lee,J. Y.; Lee, J. S.; Park, W. J.; Kim, Y. T.; Kim, S. H.; Kim, J. H.; Lim, J.-K. WO 2018139876.

 “Novel pyrimidine compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer and inflammatory diseases” Lee, K.; Choi, G.; Lee, N. R.; Park, S. J.; Jung, M. E.; Kim, S. J.; Yang, K.-M.; Lee, J. WO 2018088749.

“Pyrrolidine carboxamido derivatives and methods for preparing and using the same” Choi, G.; Rhee, S. D.; Ali, I.; Chae, C. H.; Park, S. H.; Jeon, M. K.; Lee, Y. S.; Lee, K. WO 2017008033.

“Pyrimidine-​2,​4-​diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient” Yun, C.- S.; Kim, H. R.; Cho, S. Y.; Jung, H. J.; Lee, K.; Chae, C. H.; Lee, C. O.; Park, C. H.; Kim, P.; Hwang, J. Y.; Ha, J. D.; Ahn, S. J. WO 2015/194764.

“Pyrimidine-​2,​4-​diamine derivative and pharmaceutical anticancer composition containing same as active ingredient” Jung, H. J.; Kim, H. R.; Kim. P.; Park, C. H.; Ahn, S. J.; Yun. C. S.; Lee, K.; Lee, C. O.; Cho, S. Y.; Chae, J. H.; Ha, J. D.; Hwang, J. Y. WO 2015/130014.

“Preparation of triazolopyrazine derivatives as tyrosine kinase inhibitors” Jung, H.; Ha, J. D.; Cho, S. Y.; Kim, H. R.; Lee, K.; Lee, C. O.; Choi, S. U.; Park, C. H. WO 2015/046653.

“Preparation of N2,​N4-​bis[4-​(piperazin-​1-​yl)​phenyl]​pyrimidine-​2,​4-​diamine derivatives for the treatment of cancer” Lee, K.; Kim, H. R.; Park, C. H.; Lee, C. O.; Lee, J. K.; Jung, H.; Cho, S. Y.; Chae, C. H.; Choi, S. U. Ha, J. D. WO 2014/025128.

“Preparation of pyrimidine compounds containing hydrazinone moiety as c-​Met tyrosine kinase inhibitors” Jung, H.; Ha, J. D.; Cho, S. Y.; Kim, H. R.; Lee, K.; Choi, S. U.; Park, C. H.; Lee, C. O. WO 2013/154303.

“Salts of an epidermal growth factor receptor kinase inhibitor” Lai, M.; Witowski, S. R.; Tester, R. W.; Lee, K. WO 2013/138502.

“Mutant-selective EGFR inhibitors and uses thereof” Lee, K.; Niu, D.; Petter, R. C.; Singh, J.; Baevsky, M. F.; Eaton, B.; Zhu, Z.; D’Agostino, L. A. WO 2012/064706.

“Heteroaryl Compounds and uses thereof” Lee, K.; Niu, D.; Petter, R. C.; Singh, J. WO 2012/061303.

“Heterocyclic Compounds and uses thereof” Lee, K.; Niu, D.; Petter, R. C.; Baevsky, M. F.; Singh, J. WO 2012/061299.

 “Ligand-directed covalent modification of protein” Petter, R. C.; Jewell, C. F.; Lee, K.; Medikonda, A. P.; Niu, D.; Qiao, L.; Singh, J.; Zhu, Z. WO 2011/082285.

“Inhibitors of undecaprenyl pyrophophate synthase” Hurley, T.; Lee, K.; Peukert, S.; Wattanasin, S. WO 2008/014307.

“Preparation of N-formyl hydroxylamine proline derivatives as peptidyl deformylase” Lee, K.; Leeds, J. WO 2007/106670.

“Preparation of N-Formyl hydroxylamine-containing” Bracken, K. R.; Bushell, S.; Dean, K.; Francavilla, C.; Jain, R. K.; Lee. K.; Seepersaud. M.; Shu, L.; Sundaram, A.; Yuan, J. WO 2006/127576.

“Oxazolidinone Derivatives and a Method for the Preparation Thereof and and Antibacterial Composition Containing the Same” Yoon, Y. H.; Kim, H. S.; Lee, K.; Lee, K. H.; Kang, J. A.; Lee, Y. H. U.S. Patent 5,929,083 July 27, 1999.

“Novel Cephem Compounds” Kim, C. S.; Ahn, Y. S.; Jung, K. Y.; Yun, R. L.; Park, S. Y.; Yoon, Y. H.; Lee, K. H.; Lyu, C. S.; Lee, K. WO 94/29321.

신약개발을 위한 의약화학연구실로 의약화학 연구수행을 위해 유기화학, 유기합성화학 등 유기화합물의 합성, 약물성을 연구하는 실험실입니다. 국내에서 기업체로 가장 많은 기술이전을 달성한 연구실로 충실한 기초교육을 받고, 새로운 것에 대한 학습의지가 있는 신입생이 함께 연구하면 좋겠습니다. NMR, Mass spectroscopy, HPLC, MPLC 등 다양한 연구기자재를 구비하고 있으며, 최신 연구주제를 연구하여 졸업 후 기업체로의 취업에 잘되는 실험실입니다. 젊은 대학원생에게 사고와 연구의 경험과 지평을 넓힐 수 있게 실험적으로 다양하고 많은 기회를 제공할 것입니다.

We do organic chemistry and synthetic chemistry for medicinal chemistry. Well-educated candidates with enthusiasm are expected to join our dynamic research team. Most updated lab instruments including NMR, Mass spectroscopy, HPLC, MPLC are available for our first-in-class research topic. You will get experience and expand your horizon with variety of research topics.